Aspirin Use among Adults with Cardiovascular Disease in the United States: Implications for an Intervention Approach
Aspirin Use among Adults with Cardiovascular Disease in the United States: Implications for an Intervention Approach
复制标题
DOI：
10.3390/jcm8020264
复制
发表时间：
2019-02-01
影响因子：
3.9
通讯作者：
Johnson, Tara
中科院分区：
文献类型：
--
作者：
Ansa, Benjamin E.;Hoffman, Zachary;Johnson, Tara
心血管疾病（CVD）是一种主要的潜在死因，在包括美国在内的大多数国家都有很高的经济负担。生活方式的改变和抗血小板治疗的使用，如阿司匹林，可以显着促进成人CVD的二级预防。本研究调查了美国成年人中阿司匹林用于心绞痛、心肌梗死（MI）和脑血管疾病（中风）二级预防的患病率和相关因素。本横断面研究分析了2015年行为风险因素监测系统（BRFSS）数据集。近16%的研究人群（N = 441，456）患有心绞痛、MI或卒中。心绞痛、心肌梗死和卒中的受访者加权百分比分别为4%、4.3%和3%。总体而言，每日（或每隔一天）服用阿司匹林的加权患病率在心绞痛、MI和卒中患者中分别约为65%、71%和57%。与阿司匹林使用显着相关的因素包括男性、高中以上教育程度、高血压、糖尿病以及总体健康状况不佳。根据诊断、人口统计学和社会经济状况，CVD患者在使用阿司匹林进行二级预防方面存在差异。促进阿司匹林使用的资源应针对利用率较低的群体。
Cardiovascular disease (CVD) is a major underlying cause of death, with high economic burden in most countries, including the United States. Lifestyle modifications and the use of antiplatelet therapy, such as aspirin, can contribute significantly to secondary prevention of CVD in adults. This study examined the prevalence and associated factors of aspirin use for the secondary prevention of angina pectoris, myocardial infarction (MI), and cerebrovascular disease (stroke) in a sample of American adults. The 2015 Behavioral Risk Factor Surveillance System (BRFSS) dataset was analyzed for this cross-sectional study. Almost 16% of the study population (N = 441,456) had angina, MI, or stroke. Weighted percentages of respondents with angina, MI, and stroke were 4%, 4.3%, and 3%, respectively. Overall, weighted prevalence of daily (or every other day) aspirin use was about 65%, 71%, and 57% among respondents with angina, MI, and stroke, respectively. Factors that were significantly associated with aspirin use included male sex, more than high school education, high blood pressure, diabetes, and less than excellent general health. There were existing differences among individuals with CVD based on diagnosis, demographic and socioeconomic status in the use of aspirin for secondary prevention. Resources for promoting aspirin use should be directed toward groups with lower utilization.